Abstract
Purpose
Certain clinicopathological factors contribute to the development of venous thromboembolism (VTE) in lung cancer. The aim of the current study was to assess the incidence of and the potential risk factors associated with the development of VTE in Chinese lung cancer patients.
Methods
Patients with lung cancer in our center were screened for VTE from January 2004 to July 2013. One VTE case was matched with two controls according to gender, pathology, clinical stage, and anticancer therapy.
Results
Among the 4,726 patient records screened, 61 (1.3 %) VTE cases with non-small cell lung cancer (NSCLC) were identified, including 58 (95.1 %) with adenocarcinoma and 59 (96.7 %) with advanced stage tumors (IIIb and IV). Serous effusion (OR 2.089, 95 % CI 1.022–4.270, P = 0.043), fever (OR 8.999, 95 % CI 1.688–47.968, P = 0.010), increased leukocytes (OR 4.136, 95 % CI 1.957–8.738, P < 0.001), hyponatremia (<130 mmol/L, OR 5.335, 95 % CI 1.366–20.833, P = 0.016), and increased alanine aminotransferase (ALT) (OR 3.879, 95 % CI 1.514–9.936, P = 0.005) were associated with an increased risk of VTE. Patients with poor performance status (PS) (≥2 vs. <1) (HR 1.574, 95 % CI 1.112–2.228, P = 0.010) and serous effusion (HR 1.571, 95% CI 1.114–2.215, P = 0.010) tended to have a poor prognosis. There was no difference in overall survival between VTE (median 15.2 months, 95 % CI 11.6–18.9) and control patients (median 16.3 months, 95 % CI 14.1–18.4, P = 0.184; HR 1.273, 95 % CI 0.890–1.820, P = 0.185).
Conclusions
Clinical characteristics such as serous effusion, fever, increased leukocytes, hyponatremia, and increased ALT are potential risk factors for VTE in NSCLC. Poor PS and serous effusion imply poor prognosis for NSCLC patients, most of which have adenocarcinomas and advanced stage.
Similar content being viewed by others
References
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90
He J, Gu D, Wu X, Reynolds K, Duan X, Yao C, Wang J, Chen CS, Chen J, Wildman RP, Klag MJ, Whelton PK (2005) Major causes of death among men and women in China. N Engl J Med 353:1124–1134
Guo P, Huang ZL, Yu P, Li K (2012) Trends in cancer mortality in China: an update. Ann Oncol 23:2755–2762
Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA (2000) Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343:1846–1850
Scotte F, Rey JB, Launay-Vacher V (2012) Thrombosis, cancer and renal insufficiency: low molecular weight heparin at the crossroads. Support Care Cancer 20:3033–3042
Chew HK, Davies AM, Wun T, Harvey D, Zhou H, White RH (2008) The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost 6:601–608
Tagalakis V, Levi D, Agulnik JS, Cohen V, Kasymjanova G, Small D (2007) High risk of deep vein thrombosis in patients with non-small cell lung cancer: a cohort study of 493 patients. J Thorac Oncol 2:729–734
Agnelli G, Verso M, Mandala M, Gallus S, Cimminiello C, Apolone G, Di Minno G, Maiello E, Prandoni P, Santoro A, Crino L, Labianca R (2013) A prospective study on survival in cancer patients with and without venous thromboembolism. Intern Emerg Med 9:559–567
Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R, Quehenberger P, Zielinski C, Pabinger I (2010) Prediction of venous thromboembolism in cancer patients. Blood 116:5377–5382
Wang Z, Wu YL, Zhang GC, Zhou Q, Xu CR, Guo AL (2008) EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients. Onkologie 31:174–178
An SJ, Chen ZH, Su J, Zhang XC, Zhong WZ, Yang JJ, Zhou Q, Yang XN, Huang L, Guan JL, Nie Q, Yan HH, Mok TS, Wu YL (2012) Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS One 7:e40109
White RH (2003) The epidemiology of venous thromboembolism. Circulation 107:I4–8
Tesselaar ET, Osanto S (2007) Risk of venous thromboembolism in lung cancer. Curr Opin Pulm Med 13:362–367
Verso M, Gussoni G, Agnelli G (2010) Prevention of venous thromboembolism in patients with advanced lung cancer receiving chemotherapy: a combined analysis of the PROTECHT and TOPIC-2 studies. J Thromb Haemost 8:1649–1651
Lyman GH, Eckert L, Wang Y, Wang H, Cohen A (2013) Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis. Oncologist 18:1321–1329
Walsh KA, Lewis DA, Clifford TM, Hundley JC, Gokun Y, Angulo P, Davis GA (2013) Risk factors for venous thromboembolism in patients with chronic liver disease. Ann Pharmacother 47:333–339
Cheng YJ, Liu ZH, Yao FJ, Zeng WT, Zheng DD, Dong YG, Wu SH (2013) Current and former smoking and risk for venous thromboembolism: a systematic review and meta-analysis. PLoS Med 10:e1001515
Pabinger I, Thaler J, Ay C (2013) Biomarkers for prediction of venous thromboembolism in cancer. Blood 122:2011–2018
Zakai NA, McClure LA (2011) Racial differences in venous thromboembolism. J Thromb Haemost 9:1877–1882
Fang C, Cohen HW, Billett HH (2013) Race, ABO blood group, and venous thromboembolism risk: not black and white. Transfusion 53:187–192
Sugiura S, Ando Y, Minami H, Ando M, Sakai S, Shimokata K (1997) Prognostic value of pleural effusion in patients with non-small cell lung cancer. Clin Cancer Res 3:47–50
Agnelli G, Gussoni G, Bianchini C, Verso M, Mandala M, Cavanna L, Barni S, Labianca R, Buzzi F, Scambia G, Passalacqua R, Ricci S, Gasparini G, Lorusso V, Bonizzoni E, Tonato M (2009) Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 10:943–949
Agnelli G, Verso M (2010) Thromboprophylaxis during chemotherapy in patients with advanced cancer. Thromb Res 125(Suppl 2):S17–20
Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, Laporte S, Faivre R, Charbonnier B, Barral FG, Huet Y, Simonneau G (1998) A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du risque d’embolie pulmonaire par interruption Cave study group. N Engl J Med 338:409–415
Galipienzo J, Garcia de Tena J, Flores J, Alvarez C, Alonso-Viteri S, Ruiz A (2010) Safety of withholding anticoagulant therapy in patients with suspected pulmonary embolism with a negative multislice computed tomography pulmonary angiography. Eur J Intern Med 21:283–288
Acknowledgments
This study was partially supported by medical assistant Chao-Ping Chen of the cancer center.
Conflict of interest
There were no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
The English in this document has been checked by at least two professional editors, both native speakers of English. For a certificate, please see: http://www.textcheck.com/certificate/dyVTjV.
Rights and permissions
About this article
Cite this article
Wang, Z., Yan, HH., Yang, JJ. et al. Venous thromboembolism risk factors in Chinese non-small cell lung cancer patients. Support Care Cancer 23, 635–641 (2015). https://doi.org/10.1007/s00520-014-2405-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-014-2405-y